Kailash Singh | Molecular Biology | Best Researcher Award

Posted on by Shen Awards

Dr. Kailash Singh | Molecular Biology | Best Researcher Award

Senior Consultant from The University of Hong Kong.

Dr. Kailash Singh is a distinguished researcher and senior consultant specializing in life sciences, with a focus on early drug discovery, oncology, virology, and regulatory science. He has made significant contributions to the development of therapeutic agents targeting hypertension, cancer, and infectious diseases. His work has garnered 442 citations, with an h-index of 12, reflecting sustained impact in his field. Dr. Singh has published 22 peer-reviewed articles, authored a book chapter, and holds a patent for a novel allosteric modulator for hypertension. He is a member of the American Association for Cancer Research (AACR) and actively participates in drug discovery and regulatory science communities. His collaborations with renowned researchers and institutions worldwide underscore his global research network.

Professional Profile

Education:

Dr. Singh’s academic journey is marked by a commitment to excellence in life sciences. He earned his Ph.D. in Biology from the University of Hong Kong, where he conducted pioneering research in molecular biology and pharmacology. In addition to his doctoral studies, he pursued an MBA from Copenhagen Business School, equipping him with a strong foundation in business and management principles. This combination of scientific and business education has enabled Dr. Singh to bridge the gap between research and industry, fostering innovation and facilitating the translation of scientific discoveries into practical applications.

Professional Experience:

Dr. Singh’s professional career spans academia, industry, and consulting, reflecting his versatility and expertise. As a Senior Consultant at Devote Consulting, he provides strategic guidance on regulatory compliance, including MDR and FDA 510(k) submissions in the biotechnology sector. His previous roles include serving as a Strategy Analyst at LEO Pharma, where he led market analyses and competitive reports for major projects. At ImmunoDiagnostics Limited, he managed the establishment of a diagnostic lab and developed targeted go-to-market strategies. As a founding partner of PhrmaSec Limited, Dr. Singh played a vital role in securing funding for research initiatives. His academic tenure as a Postdoctoral Researcher at the University of Hong Kong involved leading interdisciplinary projects and fostering collaborations within the scientific community.

Research Interests:

Dr. Singh’s research interests are diverse and encompass several critical areas in life sciences. He focuses on early drug discovery and pre-clinical research, particularly in developing novel therapeutic agents for hypertension, cancer, and infectious diseases. His work on allosteric modulators for G protein-coupled receptors (GPCRs) has significant implications for drug development. Additionally, Dr. Singh investigates biomarkers for neurodegenerative diseases, aiming to enhance diagnostic and therapeutic strategies. His expertise extends to Software as a Medical Device (SaMD) and in vitro diagnostic (IVD) regulatory compliance, ensuring that innovative medical technologies meet stringent regulatory standards.

Research Skills:

Dr. Singh possesses a comprehensive skill set that spans various aspects of life sciences research. He is proficient in molecular biology techniques, including cell culture, biochemical assays, and molecular dynamics simulations. His expertise in bioinformatics enables him to analyze complex biological data, facilitating the identification of potential drug targets. Dr. Singh has experience in developing standard operating procedures (SOPs) for the production of in vitro diagnostic products, optimizing quality and reproducibility. His project management skills are demonstrated through the successful completion of multiple research projects and the establishment of diagnostic services. Additionally, he has contributed to securing research funding and has a strong background in scientific writing, with numerous publications in high-impact journals.

Conclusion:

Dr. Kailash Singh’s extensive academic background, diverse professional experience, and significant research contributions underscore his standing as a leading figure in life sciences. His interdisciplinary expertise bridges the gap between scientific research and industry application, fostering innovation and advancing healthcare solutions. Dr. Singh’s commitment to excellence is evident in his numerous publications, patents, and active participation in professional communities. His dedication to mentoring emerging scientists and his collaborative approach to research further enhance his impact in the scientific community. Dr. Singh’s work continues to inspire and influence the fields of drug discovery, regulatory science, and translational research.

Publication Top Notes

  • “A novel small-molecule inhibitor of influenza A virus acts by suppressing PA endonuclease activity of the viral polymerase”
    • Authors: Shuofeng Yuan, Hin Chu, Kailash Singh, Hanjun Zhao, Ke Zhang, Richard Y.T. Kao, Billy K.C. Chow, Jie Zhou, Bo-Jian Zheng
    • Year: 2016
    • Citations: 51
    • Source: Scientific Reports, Volume 6, Article 22880
    • DOI: 10.1038/srep22880
    • Summary: This study identifies a small-molecule compound, ANA-0, that inhibits the replication of multiple subtypes of influenza A virus by suppressing the PA endonuclease activity of the viral polymerase.
  • “PB2 substitutions V598T/I increase the virulence of H7N9 influenza A virus in mammals”
    • Authors: Meng Hu, Shuofeng Yuan, Ke Zhang, Kailash Singh, Qiang Ma, Jie Zhou, Hin Chu, Bo-Jian Zheng
    • Year: 2017
    • Citations: 50
    • Source: Virology, Volume 501, Pages 92-101
    • DOI: 10.1016/j.virol.2016.11.008
    • Summary: The research demonstrates that PB2 substitutions V598T/I enhance the replication and virulence of H7N9 influenza A virus in mammalian models.
  • “Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase”
    • Authors: Shuofeng Yuan, Hin Chu, Hanjun Zhao, Ke Zhang, Kailash Singh, Billy K.C. Chow, Richard Y.T. Kao, Jie Zhou, Bo-Jian Zheng
    • Year: 2016
    • Citations: 49
    • Source: Antiviral Research, Volume 125, Pages 34-42
    • DOI: 10.1016/j.antiviral.2015.11.005
    • Summary: This paper reports the identification of a small-molecule inhibitor that disrupts the interaction between subunits of the influenza virus polymerase, thereby inhibiting viral replication.
  • “Cross-protection of influenza A virus infection by a DNA aptamer targeting the PA endonuclease domain”
    • Authors: Shuofeng Yuan, N. Zhang, Kailash Singh, H. Shuai, Hin Chu, Jie Zhou, Billy K.C. Chow, Bo-Jian Zheng
    • Year: 2015
    • Citations: 47
    • Source: Antimicrobial Agents and Chemotherapy, Volume 59, Issue 7, Pages 4082-4093
    • DOI: 10.1128/AAC.04847-14
    • Summary: The study investigates the use of a DNA aptamer targeting the PA endonuclease domain of influenza A virus, demonstrating its potential for cross-protection against various influenza strains.
  • “A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication”
    • Authors: Shuofeng Yuan, Hin Chu, Ke Zhang, Jie Ye, Kailash Singh, Richard Y.T. Kao, Billy K.C. Chow, Jie Zhou, Bo-Jian Zheng
    • Year: 2016
    • Citations: 36
    • Source: Journal of Antimicrobial Chemotherapy, Volume 71, Issue 9, Pages 2489-2497
    • DOI: 10.1093/jac/dkw194
    • Summary: This research identifies a small-molecule compound that disrupts the PB2 cap-binding activity of the influenza A virus, effectively inhibiting viral replication.
  • “Amino acid substitutions V63I or A37S/I61T/V63I/V100A in the PA N-terminal domain increase the virulence of H7N7 influenza A virus”
    • Authors: Meng Hu, Hin Chu, Ke Zhang, Kailash Singh, C. Li, Shuofeng Yuan, Billy K.C. Chow, W. Song, Bo-Jian Zheng
    • Year: 2016
    • Citations: 31
    • Source: Scientific Reports, Volume 6, Article 37800
    • DOI: 10.1038/srep37800
    • Summary: The study explores how specific amino acid substitutions in the PA N-terminal domain can enhance the virulence of H7N7 influenza A virus in mammalian hosts.
  • “Pharmacological actions of glucagon-like peptide-1, gastric inhibitory polypeptide, and glucagon”
    • Authors: R. Sekar, Kailash Singh, A.W.R. Arokiaraj, Billy K.C. Chow
    • Year: 2016
    • Citations: 29

Pi-Wan Cheng | Molecular Biology | Best Researcher Award

Posted on by Shen Awards

Prof. Dr. Pi-Wan Cheng | Molecular Biology | Best Researcher Award

Professor at University of Nebraska Medical Center, United States

Dr. Pi Wan Cheng is a distinguished biochemist and molecular biologist with over four decades of experience in research and academia. He currently holds a professorship at the University of Nebraska Medical Center (UNMC) and has contributed significantly to the field of glycobiology. Dr. Cheng has made pivotal advancements in understanding glycan biosynthesis and its role in health, diseases, and cancer. His work, which bridges basic and translational research, is supported by multiple research grants and patents. He has also been an active member of several professional organizations, underscoring his influence in the scientific community. Dr. Cheng’s research focuses on how glycosylation affects immune responses and cancer progression, with a special emphasis on the development of Siglec-7-based therapies for pancreatic cancer.

Professional Profile

Education:

Dr. Pi Wan Cheng obtained his Ph.D. in Biochemistry from Case Western Reserve University, Cleveland, Ohio, in 1975. Prior to that, he earned his M.S. in Biochemistry from National Taiwan University in 1968, following his B.S. in Agricultural Chemistry from the same institution in 1965. Throughout his educational journey, Dr. Cheng worked under the mentorship of prominent scientists such as Dr. Don M. Carlson and Dr. Kuo Huang Ling, which shaped his academic and professional growth in biochemistry and molecular biology.

Professional Experience:

Dr. Cheng’s career spans numerous prestigious academic institutions. He has held faculty positions at Case Western Reserve University, the University of North Carolina, and UNMC. At UNMC, he has been a professor in the Department of Biochemistry and Molecular Biology since 1995, where he was granted tenure in 1997. He also served as a research chemist at the Veterans Affairs Nebraska Western Iowa Health Care System from 2011 to 2017. His role at UNMC also includes courtesy appointments in the College of Pharmacy and the Eppley Institute for Cancer Research, where he has fostered collaborations and contributed to the institution’s research landscape.

Research Interest:

Dr. Cheng’s primary research interest lies in glycobiology, specifically the mechanisms of glycan biosynthesis and its impact on health and disease. His work focuses on understanding how glycans, particularly sialylated O-glycans, influence immune responses and contribute to the progression of diseases such as cancer. He investigates how specific glycans, induced by factors like interleukin-6 and alcohol, can protect cancer cells from immune surveillance and promote tumor growth. His innovative research is also exploring therapies targeting Siglec-7 for pancreatic cancer treatment, with potential applications in immunotherapy and cancer prevention.

Research Skills:

Dr. Cheng possesses a comprehensive skill set in biochemistry, molecular biology, and glycobiology. He is skilled in techniques related to protein biochemistry, glycan analysis, immunology, and cancer research. His expertise includes the development of molecular models to understand glycan interactions with immune cells, as well as employing various biochemical assays to assess glycan expression in disease states. Dr. Cheng’s proficiency extends to experimental design, grant writing, and leading interdisciplinary research teams. He has also contributed to the field through patents, underscoring his ability to translate fundamental discoveries into real-world applications.

Awards and Honors:

Throughout his career, Dr. Cheng has received numerous accolades for his groundbreaking research in glycobiology. His work has been supported by prestigious grants, including those from the Nebraska Department of Health and Human Services, where he has led multiple research projects related to cancer and immune function. He holds patents in biologically active molecule delivery, reflecting his innovative contributions to science. Dr. Cheng is a lifetime member of the Society for Glycobiology and the Society of Chinese Bioscientists in America, and he has been recognized for his service to the scientific community through various professional society memberships and community volunteer work.

Conclusion:

Dr. Pi Wan Cheng is a highly qualified candidate for the Best Researcher Award, with a distinguished career marked by significant research contributions in glycobiology, a track record of continuous funding, and active involvement in the scientific community. His innovative research, particularly in cancer immunology and glycosylation, holds great promise for medical advancements. While there is room for further interdisciplinary collaboration and publication visibility, his foundational work in glycobiology makes him a deserving nominee for this prestigious award.

Publication Top Notes

  1. Markers of malignant prostate cancer cells: Golgi localization of α-mannosidase 1A at GM130-GRASP65 site and appearance of high mannose N-glycans on cell surface
    • Authors: Cheng, P.-W., Davidson, S., Bhat, G.
    • Year: 2020
    • Citations: 12
  2. Inhibitory activity of salivary glycoproteins on phytohemagglutins (PHA): Possible molecules to enhance nutritional quality of red kidney beans
    • Authors: Chachadi, V.B., Nayanegali, T.R., Pujari, B.G., Inamdar, S.R., Cheng, P.-W.
    • Year: 2020
    • Citations: 3
  3. p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance
    • Authors: Miller, D.R., Ingersoll, M.A., Chatterjee, A., Oberley-Deegan, R.E., Lin, M.-F.
    • Year: 2019
    • Citations: 18
  4. Shifted Golgi targeting of glycosyltransferases and α-mannosidase IA from giantin to GM130-GRASP65 results in formation of high mannose N-glycans in aggressive prostate cancer cells
    • Authors: Bhat, G., Hothpet, V.-R., Lin, M.-F., Cheng, P.-W.
    • Year: 2017
    • Citations: 18
  5. The role of Rab6a and phosphorylation of non-muscle myosin IIA tailpiece in alcohol-induced Golgi disorganization
    • Authors: Petrosyan, A., Casey, C.A., Cheng, P.-W.
    • Year: 2016
    • Citations: 22
  6. Downregulation of the small GTPase SAR1A: A key event underlying alcohol-induced Golgi fragmentation in hepatocytes
    • Authors: Petrosyan, A., Cheng, P.-W., Clemens, D.L., Casey, C.A.
    • Year: 2015
    • Citations: 20
  7. Glycosyltransferases involved in the synthesis of MUC-associated metastasis-promoting selectin ligands
    • Authors: Chachadi, V.B., Bhat, G., Cheng, P.-W.
    • Year: 2015
    • Citations: 15
  8. Keratin 1 plays a critical role in Golgi localization of core 2 N-acetylglucosaminyltransferase M via interaction with its cytoplasmic tail
    • Authors: Petrosyan, A., Ali, M.F., Cheng, P.-W.
    • Year: 2015
    • Citations: 20
  9. Restoration of compact Golgi morphology in advanced prostate cancer enhances susceptibility to galectin-1-induced apoptosis by modifying mucin O-glycan synthesis
    • Authors: Petrosyan, A., Holzapfel, M.S., Muirhead, D.E., Cheng, P.-W.
    • Year: 2014
    • Citations: 64
  10. Golgi fragmentation induced by heat shock or inhibition of heat shock proteins is mediated by non-muscle myosin IIA via its interaction with glycosyltransferases
    • Authors: Petrosyan, A., Cheng, P.-W.
    • Year: 2014
    • Citations: 24

 

Rui Wen | Molecular Biology | Best Researcher Award

Posted on by Shen Awards

Assist. Prof. Dr. Rui Wen | Molecular Biology | Best Researcher Award

Assistant Professor Dr at Wenzhou Medical University, China

Rui Wen, an Assistant Professor at Wenzhou Medical University in China, has focused on advancing research in biomaterials, with a special interest in silk proteins for drug delivery systems. Since earning his PhD in Biomaterials from Donghua University in 2020, Rui has quickly established a reputable profile through his publications in high-impact journals and his role in editorial positions. His work encompasses essential biological processes like protein function, alternative splicing, and gene expression, with an emphasis on the use of silk-based materials for medical applications. Rui is actively involved in peer-reviewed publications, authoring eight first-author or corresponding-author articles in prominent journals over the past five years. Additionally, he has contributed to the scientific community by serving as an editorial board member and reviewer for multiple journals, illustrating his influence and expertise in the field of biomaterials.

Professional Profile

Education

Rui Wen completed his PhD in Biomaterials at Donghua University in 2020, where he focused on the biological functions of protein materials, especially silk-based biomaterials for drug delivery. His doctoral research established foundational insights into protein functionality and biomimetic applications, shaping his future focus on protein function and genetic analysis. Throughout his education, Rui developed a sophisticated understanding of biomaterials science, from molecular genetics to applications in medical technology. His PhD laid a robust academic and technical foundation, equipping him with the essential research methodologies and laboratory skills needed to contribute meaningfully to the biomaterials field. The strong academic training he received at Donghua University, combined with hands-on experience in research, has been instrumental in his transition to his current role as an Assistant Professor, where he continues to leverage his expertise in gene expression and protein function.

Professional Experience

Rui Wen’s professional journey as an Assistant Professor at Wenzhou Medical University began shortly after he completed his PhD. In this role, Rui has focused his research on developing silk-based biomaterials for medical applications, such as drug delivery. His work often involves collaborations with other experts in the biomaterials and genetic research fields, emphasizing protein functionality and biomimetic design. Rui’s academic contributions include publishing eight peer-reviewed papers as the first or corresponding author in recognized journals, including Acta Biomaterialia and the International Journal of Biological Macromolecules. These achievements highlight his commitment to advancing scientific knowledge in biomaterials. Additionally, Rui serves on editorial boards for journals like the World Journal of Biological Chemistry, further underscoring his dedication to scientific excellence and community engagement. His involvement in these roles signifies his professional growth and increasing impact within the scientific community.

Research Interests

Rui Wen’s research interests are centered on protein function, gene expression, and biomaterials, particularly focusing on the medical potential of silk-based proteins. He is intrigued by the genetic underpinnings of protein function and the application of alternative splicing in creating materials that mimic biological functions. His work has a dual focus: understanding protein behavior at a genetic level and leveraging this knowledge to develop innovative biomaterials for drug delivery. This focus on silk-based proteins, a biologically compatible and robust material, has led Rui to explore how protein sequences can be harnessed to design highly specialized biomaterials with practical medical applications. Rui’s research aims to integrate genetic insights with material science to produce versatile, biocompatible materials that can advance drug delivery and other medical therapies, contributing to new solutions in biotechnology and healthcare.

Research Skills

Rui Wen possesses extensive research skills in biomaterials science and protein analysis. His expertise includes characterizing protein functionality, analyzing gene sequences, and applying genetic engineering principles to create innovative materials. Rui has a strong background in protein biochemistry and molecular biology, which has enabled him to identify and engineer silk proteins for biomimetic applications. Additionally, he is skilled in alternative splicing and concerted evolution, both of which play a crucial role in his work with gene expression. Rui’s laboratory skills include various analytical techniques, such as protein characterization assays, molecular modeling, and genetic sequencing. His ability to publish consistently in peer-reviewed journals reflects his proficiency in scientific communication and data analysis. Furthermore, his role as a reviewer and editor highlights his critical assessment skills, making him a valuable contributor to the scientific community.

Awards and Honors

Rui Wen’s contributions to biomaterials science have been recognized through multiple awards and honors. He received funding from the China Postdoctoral Science Foundation, a competitive grant that supports emerging researchers in China. This funding enabled him to continue his exploration of silk-based proteins and their applications in drug delivery. His role on the editorial boards of respected journals like the World Journal of Biological Chemistry and Biomedical Engineering Communications is another notable achievement, reflecting the respect he has earned among his peers. In addition, his status as an invited reviewer for journals such as the International Journal of Biological Macromolecules demonstrates his expertise and the high regard of the scientific community. These honors underscore Rui’s dedication to advancing biomaterials science and highlight his influence in the fields of protein function and gene expression.

Conclusion

Rui Wen is a dedicated and promising researcher whose accomplishments in the specialized areas of protein function and biomaterials are commendable for someone early in their career. His expertise, consistent publication record, and increasing engagement with the scientific community through editorial and reviewing activities make him a competitive candidate for the Best Researcher Award. With further developments in his citation impact and expanded international collaborations, Rui Wen’s contributions are likely to gain even greater visibility and influence, establishing him as a key figure in biomaterials research.

Publications Top Notes

  1. Title: Physical Properties of the Second Type of Aciniform Spidroin (AcSp2) from Neoscona theisi Reveal a pH-Dependent Self-Assembly Repetitive Domain
    Authors: Yang, D., Wang, S., Wang, K., Zan, X., Wen, R.
    Journal: ACS Biomaterials Science and Engineering
    Year: 2023
    Volume(Issue): 9(12)
    Pages: 6670–6682
    Citations: 1
  2. Title: Complete Gene Sequence and Mechanical Property of the Fourth Type of Major Ampullate Silk Protein
    Authors: Wen, R., Wang, S., Wang, K., Zan, X., Meng, Q.
    Journal: Acta Biomaterialia
    Year: 2023
    Volume: 155
    Pages: 282–291
    Citations: 4
  3. Title: Characterization of Two Full-Length Tubuliform Silk Gene Sequences from Neoscona theisi Reveals Intragenic Concerted Evolution and Multiple Copies in Genome
    Authors: Wen, R., Wang, K., Zan, X.
    Journal: International Journal of Biological Macromolecules
    Year: 2022
    Volume: 223
    Pages: 1015–1023
    Citations: 3
  4. Title: Characterization of Two Full-Length Araneus ventricosus Major Ampullate Silk Protein Genes
    Authors: Wen, R., Yang, D., Wang, K., Zan, X.
    Journal: International Journal of Biological Macromolecules
    Year: 2022
    Volume: 213
    Pages: 297–304
  5. Title: The Novel Aciniform Silk Protein (AcSp2-v2) Reveals the Unique Repetitive Domain with High Acid and Thermal Stability and Self-Assembly Capability
    Authors: Wen, R., Wang, K., Yang, D., Zan, X., Meng, Q.
    Journal: International Journal of Biological Macromolecules
    Year: 2022
    Volume: 202
    Pages: 91–101
    Citations: 6
  6. Title: Customized Flagelliform Spidroins Form Spider Silk-Like Fibers at pH 8.0 with Outstanding Tensile Strength
    Authors: Li, X., Qi, X., Cai, Y.-M., Meng, Q., Chen, G.
    Journal: ACS Biomaterials Science and Engineering
    Year: 2022
    Volume(Issue): 8(1)
    Pages: 119–127
    Citations: 14
  7. Title: Characterization of the Second Type of Aciniform Spidroin (AcSp2) Provides New Insight into Design for Spidroin-Based Biomaterials
    Authors: Wen, R., Wang, K., Meng, Q.
    Journal: Acta Biomaterialia
    Year: 2020
    Volume: 115
    Pages: 210–219
    Citations: 16
  8. Title: Two Novel Tubuliform Silk Gene Sequences from Araneus ventricosus Provide Evidence for Multiple Loci in Genome
    Authors: Wen, R., Wang, K., Meng, Q.
    Journal: International Journal of Biological Macromolecules
    Year: 2020
    Volume: 160
    Pages: 806–813
    Citations: 10
  9. Title: Wet-Spinning Synthetic Fibers from Aggregate Glue: Aggregate Spidroin 1 (AgSp1)
    Authors: Li, X., Mi, J., Wen, R., Meng, Q., Lin, Y.
    Journal: ACS Applied Bio Materials
    Year: 2020
    Volume(Issue): 3(9)
    Pages: 5957–5965
    Citations: 10
  10. Title: Novel Highly Soluble Chimeric Recombinant Spidroins with High Yield
    Authors: Jia, Q., Wen, R., Meng, Q.
    Journal: International Journal of Molecular Sciences
    Year: 2020
    Volume(Issue): 21(18)
    Pages: 1–13, Article ID: 6905
    Citations: 11